載入中
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
前收盤價
US$30.47
+US$0.21 · +0.69%
盤中時間採用ET。市場資料可能有所延遲。
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
日內區間
目前US$30.47
52週區間
目前US$30.47
盤中時間採用ET。市場資料可能有所延遲。
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
日內區間
目前US$30.47
52週區間
目前US$30.47
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 40.9萬 USD | — | — | — | — |
| 毛利 | −40.9萬 USD | — | — | — | — |
| 研究與開發 | 4.57億 USD | 3.61億 USD | 2.13億 USD | 1.6億 USD | 1.02億 USD |
| 銷售、一般及管理費用 | 7624.2萬 USD | 7723.5萬 USD | 5728.1萬 USD | 4801.9萬 USD | 5422.5萬 USD |
| 營業費用 | 5.33億 USD | 4.38億 USD | 2.7億 USD | 2.08億 USD | 1.56億 USD |
| 利息收入 | 2533萬 USD | 2473.2萬 USD | 2494.8萬 USD | 757.8萬 USD | — |
| 利息支出 | — | — | — | 1248.2萬 USD | — |
| 折舊和攤銷 | 40.9萬 USD | 37.7萬 USD | 23.1萬 USD | 19.3萬 USD | 12.6萬 USD |
| 營業利益 | −5.33億 USD | −4.38億 USD | −2.7億 USD | −2.08億 USD | −1.56億 USD |
| 淨利 | −5.06億 USD | −4.14億 USD | −2.59億 USD | −2.11億 USD | −1.57億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$40.00
上漲空間 31.28%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.06億0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB7708.42萬0.04%1853億 USD0.03%US$289.48+0.64%
iShares Russell 2000 ETFIWM6925.95萬0.09%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI6462.55萬0.65%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK4436.92萬0.10%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF3662.12萬0.04%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO2415.23萬0.18%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO2002.07萬0.11%180億 USD0.06%US$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
